Market Overview

Acorda Therapeutics Completes Neuronex Acquisition

Acorda Therapeutics (NASDAQ: ACOR) today announced that the
Company has completed the acquisition of Neuronex, Inc., a privately
held company developing a nasal spray formulation of diazepam. Under the
terms of the agreement, Acorda paid $6.8 million to Neuronex to complete
the acquisition.

“Diazepam Nasal Spray is an important addition to our pipeline and
aligns with our core strategy to develop and commercialize products that
offer unique benefits to people with neurological diseases,” said Ron
Cohen, M.D., Acorda's President and CEO. “This product leverages our
existing sales, marketing and medical organizations, which have proved
highly successful in bringing novel neurological therapies to market.”

Diazepam Nasal Spray is

See full press release

Posted-In: News Guidance Contracts Management Stock Split M&A Global

 

Related Articles (ACOR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters